Crossmark

Risk of major adverse cardiovascular events with aripiprazole versus olanzapine, quetiapine, and risperidone in severe mental illness: a target trial emulation

Crossref DOI link: https://doi.org/10.1038/s41467-025-67843-w

Published Online: 2025-12-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Richards-Belle, Alvin https://orcid.org/0000-0001-8577-9380
Launders, Naomi https://orcid.org/0000-0003-4241-938X
Hardoon, Sarah

Man, Kenneth K. C. https://orcid.org/0000-0001-8645-1942
Davies, Neil M. https://orcid.org/0000-0002-2460-0508
Bramon, Elvira https://orcid.org/0000-0003-1369-5983
Hayes, Joseph F.

Osborn, David P. J.
License Information

Text and Data Mining valid from 2025-12-21

Version of Record valid from 2026-01-28
More Information

Article History

Received: 25 March 2025

Accepted: 9 December 2025

First Online: 21 December 2025

Competing interests

: JFH has received consultancy fees from Wellcome Trust, juli Inc and Swiss Re unrelated to the results of the current study. All other authors declare no competing interests.

Document is current

Any future updates will be listed below